Nektar Therapeutics (NKTR) Sees Unusually-High Trading Volume

Nektar Therapeutics (NASDAQ:NKTR) saw an uptick in trading volume on Tuesday . 5,983,259 shares changed hands during trading, an increase of 161% from the previous session’s volume of 2,296,566 shares.The stock last traded at $68.03 and had previously closed at $57.40.

A number of brokerages have recently commented on NKTR. Mizuho began coverage on shares of Nektar Therapeutics in a report on Tuesday, September 26th. They set a “buy” rating and a $30.00 price target for the company. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Canaccord Genuity lifted their price target on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, November 13th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a report on Monday, November 13th. Finally, Jefferies Group reiterated a “buy” rating and set a $35.00 price target on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Nektar Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $35.58.

The stock has a market capitalization of $10,710.00, a price-to-earnings ratio of -95.82 and a beta of 1.81. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm had revenue of $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. During the same period in the previous year, the firm earned ($0.32) earnings per share. Nektar Therapeutics’s revenue was up 321.2% compared to the same quarter last year. equities analysts predict that Nektar Therapeutics will post -0.75 earnings per share for the current fiscal year.

In related news, Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total value of $1,759,800.00. Following the completion of the sale, the director now directly owns 70,500 shares in the company, valued at $4,135,530. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Howard W. Robin sold 83,333 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total transaction of $4,640,814.77. Following the completion of the sale, the chief executive officer now owns 272,768 shares of the company’s stock, valued at $15,190,449.92. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 614,017 shares of company stock valued at $20,587,527. 5.44% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 692 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Nektar Therapeutics by 7.7% in the second quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 929 shares during the period. Amalgamated Bank grew its holdings in Nektar Therapeutics by 8.7% in the second quarter. Amalgamated Bank now owns 20,563 shares of the biopharmaceutical company’s stock valued at $402,000 after purchasing an additional 1,644 shares during the period. Shelton Capital Management grew its holdings in Nektar Therapeutics by 12.5% in the second quarter. Shelton Capital Management now owns 15,283 shares of the biopharmaceutical company’s stock valued at $299,000 after purchasing an additional 1,696 shares during the period. Finally, Strs Ohio grew its holdings in Nektar Therapeutics by 16.3% in the third quarter. Strs Ohio now owns 16,400 shares of the biopharmaceutical company’s stock valued at $393,000 after purchasing an additional 2,300 shares during the period. Hedge funds and other institutional investors own 96.01% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/09/nektar-therapeutics-nktr-sees-unusually-high-trading-volume.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit